Cite
P2.05-10 The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome.
MLA
Li, A., et al. “P2.05-10 The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes Is Determined by Tumor Transcriptome.” Journal of Thoracic Oncology, vol. 18, no. 11, Nov. 2023, pp. S311–12. EBSCOhost, https://doi.org/10.1016/j.jtho.2023.09.537.
APA
Li, A., Luo, L., Du, W., He, L., Fu, S., Wang, Y., Yu, Z., Yang, Y., Fang, W., Zhang, L., & Hong, S. (2023). P2.05-10 The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome. Journal of Thoracic Oncology, 18(11), S311–S312. https://doi.org/10.1016/j.jtho.2023.09.537
Chicago
Li, A., L. Luo, W. Du, L. He, S. Fu, Y. Wang, Z. Yu, et al. 2023. “P2.05-10 The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes Is Determined by Tumor Transcriptome.” Journal of Thoracic Oncology 18 (11): S311–12. doi:10.1016/j.jtho.2023.09.537.